Careers  |  Sign In  |  Register  |   Twitter

Latest in Public Health & Prevention

Sovaldi, Gilead Sciences Inc.'s hepatitis C drug which currently costs $1,000 per pill, will be available in 91 developing nations at a lower cost, a Reuters article reports. Roughly 150 million people in the world have chronic hepatitis C; few of them have access to the treatment they need. Normally, the...
According to a New York Times article, the deadly Ebola outbreak in West Africa is expected to take an additional 12 to 18 months to control. Researchers and scientists at various universities have stated that at its current rate, 20,000 cases could be seen in a single month, though the World Health...
Vyvanse, an ADHD drug produced by Shire is receiving a priority review for the potential treatment of binge eating disorder, a Reuters article reports. The review comes after the FDA approval of Orexigen Therapeutic's obesity pill Contrave. Currently, Vyvanse is approved for use in treating ADHD, and...